CDC advisory group votes to add COVID-19 vaccines to the pediatric immunization schedule; a new report says workplaces can be hazardous to the mental and physical health of Americans; drug makers are lobbying to ease the impact of the Inflation Reduction Act.
CDC Advisory Group Votes to Add COVID-19 to Pediatric Immunization Schedule
In a unanimous 15-to-0 vote, the Advisory Committee on Immunization Practices (ACIP) approved adding the COVID-19 vaccine to the recommended immunizations for children, according to CIDRAP. States often use the immunization schedule as a guide, but not all states require the vaccines on the schedule. The recommendation came a day after ACIP approved adding vaccines for COVID-19 to a program that provides free vaccines for children who either can’t afford them or who are uninsured.
Work Can Be Hazardous to Mental and Physical Health
Workplaces can be hazardous to Americans’ mental health and well-being, as well as their physical health, according to a new report from the United States Surgeon General. According to STAT, the report drew attention to factors like racism, bullying, and powerlessness at work, which contribute to ill health. The report calls on companies to protect employees from physical harm, by implementing basic safety, and psychological harm, by protecting against harassment. In addition, the report calls for workers to have adequate time off.
Drug Makers Lobby Against Impacts of the IRA
The Inflation Reduction Act (IRA) gives Medicare the authority to negotiate drug prices for certain therapies, and drug makers are seeking to ease the impact of the law, reported The Wall Street Journal. Both the Biotechnology Innovation Organization and Pharmaceutical Research and Manufacturers of America, the 2 largest grade groups for the pharmaceutical industry, say the law threatens investment in drug development without doing enough to lower drug costs for patients. Both groups are working to limit the effect the law will have on drug research.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More